A Pilot Trial of Anti-PD-1 (Nivolumab) in Bladder Cancer Patients Recently Treated With Intravesical BCG Immunotherapy
Phase of Trial: Phase I
Latest Information Update: 30 May 2018
Price : $35 *
At a glance
- Drugs Nivolumab (Primary)
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- 22 May 2018 Status changed from active, no longer recruiting to discontinued.
- 26 Apr 2018 Status changed from recruiting to active, no longer recruiting.
- 12 Mar 2018 Planned End Date changed from 1 Jul 2019 to 1 Jul 2021.